introduction: binding a monoclonal antibody to tumor associated antigens is an effective method for cancer therapy because these agents can specifically target malignant cells, in fact monoclonal antibodies are effective agents for diagnosis, grading and treatment of different kinds of cancers. methods: in this research, a new monoclonal antibody against colon cancer cells was prepared and anti...

Background: Lung carcinoma is a multiple type cancer comprising of small cell and non-small cell carcinomas (NSCLC). For therapeutic and diagnostic purposes, serum monoclonal antibodies have been produced against lung cancer. Objective: To charac-terize a murine monoclonal antibody (ME3D11) reactive with human NSCLC. Methods: A murine monoclonal antibody (ME3D11) reactive with human NSCLC was s...

tumor angiogenesis shown by microvessel count (mvc) or microvessel density (mvd), is assessed by several studies as prognostic factor in some types of tumors, and also in colorectal carcinoma. this article is payed to correlation between clincopathologic factors and tumor angiogenesis. in this study, immunohistochemical techniques are used for vascular evaluation in specimens from twenty-nine c...

We have developed two monoclonal antibodies, designated 152 £12 D7 and 153 (7 A6, which have reactivity with cell surface antigens expressed on the B16 mouse melanoma. These monoclonal antibodies are produced by hybridomas resulting from the fusion of splenocytes taken from C57BL/6 mice bearing the B16-F10 tumor. The monoclonal antibodies are of the ¡mmunoglobulinM class and have been shown t...

Solid tumors account for approximately 90% of all types cancer. For many tumor types, the availability effective treatment options is limited and new targeted approaches that offer potential long-term survival are warranted. Antibody-drug conjugates (ADCs) a class drugs have emerged as promising therapeutic option shown significant clinical benefit in selected malignancies. ADCs highly drugs, c...

Abstract BACKGROUND Glioblastoma multiforme (GBM) remains a disease with debilitating survival outcomes. Cancer immunogenomics represents complementary approach to the application of genomics in developing novel immunotherapies for brain malignancies. Using cancer that we developed, called Open Reading Frame Antigen Network (O.R.A.N.), identified immunogenic neoantigens and tumor-associated ant...

BACKGROUND Systemic therapy with radionuclides may be used for the treatment of patients with painful skeletal metastases owing to its efficacy, low cost and low toxicity. Imported radionuclides for pain palliation, like Strontium-89 are expensive; particularly for developing countries. In the Indian scenario, Samarium-153 (Sm-153) is produced in our own reactors and as a result, it is readily ...

We have developed two monoclonal antibodies, designated 152 E12 D7 and 153 C7 A6, which have reactivity with cell surface antigens expressed on the B16 mouse melanoma. These monoclonal antibodies are produced by hybridomas resulting from the fusion of splenocytes taken from C57BL/6 mice bearing the B16-F10 tumor. The monoclonal antibodies are of the immunoglobulin M class and have been shown to...

background: monoclonal antibodies (mabs) are essential tools for many molecular im-munology investigations, epitope mapping and molecular modelling, clinical laboratory di-agnostic tests and immunotherapy. humoral immune response of immunized animals largely depends on the nature of antigen and the immunization technique. polysaccharides and heavily-glycosylated proteins are very elusive target...